North America Dipeptidyl Peptidase-4 (DPP-4) Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The north america dipeptidyl peptidase-4 inhibitors market size is projected to expand from USD 4.72 billion in 2025 and USD 4.84 billion in 2026 to USD 5.56 billion by 2031, registering a CAGR of 2.81% between 2026 to 2031. This report is Segmented by Drug Type (Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Other Drug Types), Medication Type (Branded Medication, Generic Medication), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (United States, Canada, Mexico). The Market Forecasts are Provided in Terms of Value (USD).

North America Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Trends and Insights

Rising Type 2 Diabetes Burden Across North America

The North America DPP-4 inhibitors market continues to draw support from a diabetes burden that remains large, persistent, and still underdiagnosed across major countries. High-income North America recorded the highest increase in age-standardized type 2 diabetes incidence among world regions between 1990 and 2021, which points to a demand base that is not easing. In the United States, 40.1 million people had diabetes as of 2023, representing 12.0% of the total population, and 11.0 million adults remained undiagnosed, which keeps the treated pool open to further expansion as screening improves. Mexico adds another layer of demand because 13.6 million adults lived with diabetes in 2024, and 41.3% of cases were undiagnosed, leaving a large untreated group that can move into medication use over time. The ENSANUT 2021 to 2024 survey also showed that national type 2 diabetes prevalence reached 17.0% and only 33% of diagnosed patients achieved glycemic control, which supports continuing use of affordable oral therapies as access improves. As a result, the North America DPP-4 inhibitors market keeps a wide underlying patient base even when competitive intensity rises in higher value treatment lines.

Preference for Oral, Low-Hypoglycemia Therapies in Older Adults

The North America DPP-4 inhibitors market also benefits from the fact that older adults often need glucose lowering agents with simple use patterns and a low risk of hypoglycemia. The American Diabetes Association stated in its 2025 standards that DPP-4 inhibitors carry low hypoglycemia risk and are weight neutral, which makes them suitable for many adults aged 65 and older who face polypharmacy or fall risk. A June 2026 study in Cardiovascular Diabetology found notable safety signals for SGLT2 inhibitors in adults aged 80 and older, which can preserve room for DPP-4 use in a fast growing super elderly cohort. A separate 2025 study in Drugs & Aging showed lower rates of hypoglycemia, falls, and fractures for DPP-4 inhibitors versus sulfonylureas in older adults, which reinforces their role in routine maintenance therapy. This clinical profile matters because 52.1% of U.S. adults aged 65 and older had prediabetes, so the future treatment pool in this age group remains large. These care patterns help the North America DPP-4 inhibitors market hold relevance even while newer therapies draw attention in broader cardiometabolic care.

GLP-1 Receptor Agonist Substitution in Treatment Algorithms

The clearest restraint on the North American DPP-4 inhibitors market is the steady movement of treatment algorithms toward GLP-1 receptor agonists and, in some settings, other newer therapies with stronger cardiometabolic positioning. The shift narrows the addressable pool for DPP-4 inhibitors in patients with high body mass index, established cardiovascular disease, or a stronger need for weight reduction, where prescribers often look beyond older oral classes first. It also limits future pricing power because branded DPP-4 products must compete in a care model where therapeutic differentiation is being judged more heavily on outcomes beyond glycemic control. At the same time, the arrival of generic sitagliptin can soften some volume loss by keeping the class affordable for patients who still need oral treatment, but it cannot fully offset the pressure on branded value. The United States feels this restraint most strongly because commercial payer management, specialist prescribing patterns, and faster adoption of premium diabetes therapies all raise the intensity of substitution. As a result, the North America DPP-4 inhibitors market is likely to preserve a narrower but still important role rather than recover broad first line preference.

Other drivers and restraints analyzed in the detailed report include:

• Genericization and Formulary Repositioning of Legacy Brands
• Medicare and PBM Coverage for Cost-Conscious Maintenance Therapy
• Safety Signal Sensitivity Around Heart Failure and Pancreatic Risk in Labeling and Prescribing

Segment Analysis

Sitagliptin captured 41.83% of revenue in 2025, giving it the leading position within the North America DPP-4 inhibitors market and the clearest base for continued scale during the forecast period. The molecule benefits from long prescriber familiarity, broad historical use, and a well-understood place in oral diabetes management, which keeps it central even as the market moves into a lower-priced phase. Sitagliptin also remained the fastest-growing drug type with a CAGR 3.38% through 2031, which is unusual for the largest segment but logical in a period shaped by generic availability and wider access. In June 2026, Apotex launched generic sitagliptin tablets and sitagliptin and metformin hydrochloride tablets in the United States, adding concrete evidence that supply is broadening beyond the originator model. That timing matters because the North American DPP-4 inhibitors market can now pull in patients who were previously priced out of the class while still relying on a molecule that physicians already know well.

The second layer of the drug type picture is defined by how other molecules serve narrower but still important niches within the North American DPP-4 inhibitors industry. Linagliptin retained a meaningful role because no renal dose adjustment is needed across chronic kidney disease stages, which makes it especially relevant when prescribers treat older adults with renal impairment. Saxagliptin and alogliptin face a more constrained path because safety caution has weighed on their positioning, leaving less room for wide commercial expansion. Vildagliptin remained limited in North America because its regional footprint is far narrower than the leading products and does not change the overall category structure. These conditions leave sitagliptin as the main anchor of volume, while the remaining molecules compete more on clinical fit than on broad market reach. The result is a segment in which leadership is stable, but the terms of that leadership are moving from brand strength toward accessibility and substitution.

Complete Report Scope:

• By Drug Type
  • Sitagliptin
  • Saxagliptin
  • Linagliptin
  • Alogliptin
  • Vildagliptin
  • Other Drug Types
• By Medication Type
  • Branded Medication
  • Generic Medication
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country
  • United States
  • Canada
  • Mexico

List of Companies Covered in this Report:

• Apotex
• AstraZeneca
• Aurobindo Pharma
• Boehringer Ingelheim
• Cadila Pharmaceuticals Limited
• Cipla
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Glenmark Pharmaceuticals
• Hetero Labs Limited
• Lupin
• Merck
• Mylan
• Novartis
• Sandoz Group AG
• Sanofi
• Sun Pharmaceuticals Industries
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support